The KPV research peptide is a synthetic tripeptide (Lysine-Proline-Valine) representing the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, KPV is evaluated for its anti-inflammatory properties, particularly its potential to modulate NF-κB signaling pathways and preserve epithelial barrier integrity in mucosal tissue assays.
The KPV research peptide is a synthetic tripeptide (Lysine-Proline-Valine) representing the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, KPV is evaluated for its anti-inflammatory properties, particularly its potential to modulate NF-κB signaling pathways and preserve epithelial barrier integrity in mucosal tissue assays.
The KPV research peptide is a tripeptide consisting of the amino acid sequence L-lysine, L-proline, and L-valine. Synthesized as the functional C-terminal domain of the endogenous neuropeptide alpha-melanocyte-stimulating hormone (α-MSH), KPV retains the core anti-inflammatory sequence of α-MSH while omitting the melanogenic properties associated with the full-length 13-amino-acid parent peptide.
With a molecular formula of C16H30N4O4 and a low molecular weight of approximately 342.44 g/mol, KPV possesses distinct physical characteristics that facilitate cellular transport. Unlike larger peptide chains, this tripeptide demonstrates high water solubility and favorable uptake dynamics across epithelial layers via specialized transport machinery, making it an essential subject in advanced peptide research.
The primary mechanism of action characterized in preclinical literature for the KPV research peptide involves the downregulation of nuclear factor kappa B (NF-κB) activation. NF-κB is a master transcription factor governing inflammatory cascades, responsible for driving the expression of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α within eukaryotic cells.
In vitro models suggest that KPV translocates into the cytoplasm and nuclear space where it directly interferes with NF-κB p65 subunit translocation. By inhibiting the nuclear entry of this pro-inflammatory transactivator, KPV modulates downstream genomic transcriptions without causing complete immunosuppression, presenting a precise pathway for studying localized cellular inflammatory regulation.
A major area of study for researchers utilizing the kpv research peptide involves gastrointestinal pathology, specifically epithelial permeability and experimental colitis. In dextran sulfate sodium (DSS)-induced colitis rodent models, administration of KPV has been shown to attenuate histological mucosal damage, reduce myeloperoxidase (MPO) activity, and suppress local inflammatory cytokine expression.
Furthermore, cell culture assays employing human intestinal epithelial lines (such as Caco-2 and HCT116) demonstrate that KPV preserves tight junction integrity. Preclinical data show that exposure to KPV maintains normal cellular localization of key tight junction proteins—including zonula occludens-1 (ZO-1) and occludin—under inflammatory stress, thereby reducing paracellular permeability.
When designing protocols to investigate mucosal restoration and barrier kinetics, investigators frequently compare KPV against other prominent tissue-modulating compounds. Understanding how KPV differs structurally and mechanistically from alternative molecules is key to selecting the appropriate compound for specific laboratory assays.
While BPC-157 research peptide promotes tissue healing primarily through angiogenic pathways (such as VEGF upregulation) and nitric oxide modulation, KPV operates predominantly as an anti-inflammatory transcriptomic regulator via NF-κB inhibition. Conversely, larazotide research peptide acts directly as a tight-junction antagonist blocking zonulin receptors. KPV offers a distinct dual benefit by targeting both intracellular cytokine signaling and tight-junction preservation, making it a versatile control or primary agent in complex gut model systems.
The transport mechanism of KPV is highly specialized compared to non-oligopeptide molecules. In vitro cellular kinetics reveal that KPV utilizes the solute carrier family 15 member 1 (SLC15A1), commonly known as the oligopeptide transporter PepT1, for efficient cellular uptake.
PepT1 is expressed extensively on the apical membrane of intestinal epithelial cells and is often upregulated during active inflammatory conditions. Studies indicate that KPV's high affinity for PepT1 allows the tripeptide to enter target cells rapidly even at low micromolar concentrations, enabling precise, concentration-dependent cellular response assays in culture systems.
Beyond intestinal mucosal studies, the KPV research peptide is actively studied across additional tissue models. In vitro dermatological research evaluating keratinocyte and fibroblast cultures indicates that KPV reduces UV-induced cellular stress and dampens contact hypersensitivity responses by downregulating ICAM-1 and pro-inflammatory chemokine release.
Additionally, preliminary animal models investigating ocular and joint inflammation suggest that KPV can modulate macrophage polarity, encouraging a shift from the pro-inflammatory M1 phenotype toward an M2 anti-inflammatory repair phenotype. These findings support KPV's broader utility as a model tripeptide for systemic inflammatory pathway modulation.
To ensure experimental reproducibility when working with the KPV research peptide, proper laboratory preparation standard operating procedures must be followed. Lyophilized KPV powder should be reconstituted using sterile Bacteriostatic Water, Sterile Water for Injection, or phosphate-buffered saline (PBS), depending on the requirements of the biological assay.
Reconstitution should be performed by gently adding the diluent against the inner glass wall of the vial, followed by low-speed swirling. Vigorous agitation or vortexing must be avoided to prevent mechanical shearing or aggregation of the peptide structure. Once dissolved, solutions should be used immediately or aliquoted into single-use experimental containers to eliminate repetitive thermal stress.
Lyophilized KPV research peptide demonstrates high stability when maintained under appropriate environmental conditions. Unopened vials should be stored in a dry, dark environment at -20°C for short-to-medium term storage, or at -80°C for long-term storage to prevent moisture absorption and chemical degradation.
Reconstituted liquid solutions stored at 2°C to 8°C remain stable for short periods; however, researchers requiring long-term liquid assays should aliquot reconstituted solutions into sub-vials and freeze them at -20°C or colder. Repeated freeze-thaw cycles must be rigorously avoided as they compromise peptide concentration accuracy and secondary chemical stability.
For laboratory findings to remain valid and reproducible, researchers must utilize high-purity material free of synthesis byproducts, TFA salts, and microbial contamination. When evaluating suppliers of the KPV research peptide, laboratory managers must demand rigorous lot-specific analytical documentation.
PX1 Research enforces strict quality assurance protocols on every production batch. All KPV lots undergo Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm chemical purity exceeding 98%, accompanied by Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular mass. Furthermore, rigorous Chromogenic LAL assays ensure endotoxin levels remain strictly controlled below 0.01 EU/mg, preventing confounding immune-activation variables in cellular cultures.
All compounds provided by PX1 Research, including the KPV research peptide, are manufactured in state-of-the-art cGMP-compliant facilities located in the United States. Operations out of our California and Arizona logistics hubs allow for rapid, temperature-controlled distribution directly to academic institutions, private biotechnology firms, and contract research organizations (CROs).
Every shipment includes comprehensive, lot-traceable Certificates of Analysis (COAs) verified by independent ISO 17025 accredited laboratories. By combining USA synthesis, complete analytical transparency, and strict adherence to research-only standards, PX1 Research provides laboratories with the consistent purity required for reliable, publication-grade experimental outcomes.
What is the KPV research peptide?
KPV is a tripeptide consisting of Lysine-Proline-Valine. It represents the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH) and is studied in preclinical research for its anti-inflammatory and epithelial barrier-modulating mechanisms.
What is the primary mechanism of KPV in preclinical models?
Preclinical studies show that KPV works primarily by entering cells via the PepT1 transporter and inhibiting the nuclear translocation of NF-κB p65, thereby reducing the transcription of pro-inflammatory cytokines like TNF-α and IL-6.
How does PX1 Research verify the purity of KPV?
PX1 Research verifies every lot of KPV using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity analysis (>98%), Electrospray Ionization Mass Spectrometry (ESI-MS) for structural identification, and Chromogenic LAL testing for low endotoxin levels.
How should lyophilized KPV be stored upon receipt?
Lyophilized KPV should be stored in a dry, dark freezer at -20°C for short-to-medium term storage, or at -80°C for extended storage to maintain compound integrity and prevent degradation.
What diluent is recommended for reconstituting KPV for laboratory assays?
Common diluents include sterile Bacteriostatic Water, Sterile Water for Injection, or sterile phosphate-buffered saline (PBS), selected based on the specific requirements of the in vitro or cell culture protocol.
Is KPV stable after reconstitution?
Reconstituted KPV is stable for short durations when stored between 2°C and 8°C. For longer preservation of liquid stock, solutions should be divided into single-use aliquots and frozen at -20°C to avoid repeated freeze-thaw cycles.
How does KPV compare to BPC-157 in gastrointestinal research?
KPV acts primarily as a direct transcriptional inhibitor of NF-κB inflammatory pathways and tight-junction regulator, whereas BPC-157 acts predominantly through angiogenic, nitric oxide, and direct tissue-healing pathways.
Is KPV approved for human consumption or therapeutic use?
No. The KPV research peptide provided by PX1 Research is strictly designated for laboratory research use only (in vitro and preclinical studies) and is not intended for human or animal consumption, diagnostic, or therapeutic application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.